Jazz Pharmaceuticals plc diskutieren
Jazz Pharmaceuticals plc
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Aktie / Pharmazeutika / Mid Cap /
139,50 €
-1,78 %
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $183.00 price target on the stock, up previously from $175.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at HC Wainwright from $200.00 to $217.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $210.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Morgan Stanley from $183.00 to $166.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $147.00 price target on the stock, down previously from $176.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Royal Bank of Canada from $182.00 to $172.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Robert W. Baird from $167.00 to $155.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $152.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) had its price target lowered by analysts at Morgan Stanley from $166.00 to $165.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) had its price target lowered by analysts at Morgan Stanley from $165.00 to $162.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $200.00 to $205.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Royal Bank Of Canada from $145.00 to $151.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $162.00 to $185.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $163.00 to $167.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Neueste Beiträge
Sanford_C__Bernstein in KLA-Tencor Corp. diskutieren